Opendata, web and dolomites

ADDITION

Arthritis Differential DIagnostic validaTION

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ADDITION project word cloud

Explore the words cloud of the ADDITION project. It provides you a very rough idea of what is the project "ADDITION" about.

strategies    500    140m    prospective    first    complemented    efficacy    treatment    newly    feasibility    describes    methotrexate    collection    impacts    few    techniques    huge    accuracy    synovial    ea    turnover    90    ua    osteoarthritis    rheumakit    predict    ineffective    2014    trancriptomic    logistics    diagnostic    infrastructure    criterion    280m    differential    patient    market    patients    arthritis    adequacy    unjustified    subclass    solution    tool    progression    suffering    therapeutic    consists    1000    larger    economic    mistake    line    ce    genes    computing    pcr    mtx    incidence    inappropriate    validate    transportation    eular2010    seronegative    cohort    diagnosed    signature    clinicians    rheumatoid    provides    clinically    40    probabilities    spondylarthropaties    leads    involve    joints    vs    earlier    group    health    inflammation    distinction    clinical    undifferentiated    functional    cloud    diseases    ing    acr    kit    unsatisfactory    biopsy    treatments    expenses    limited    serious    web    annual    socio    central    validated    procedure    lab    useless    ra    marked   

Project "ADDITION" data sheet

The following table provides information about the project.

Coordinator
DNALYTICS 

Organization address
address: CHEMIN DU CYCLOTRON 6
city: OTTIGNIES LOUVAIN LA NEUVE
postcode: 1348
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Project website http://www.dnalytics.com. The RheumaKit online platform
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-04-01   to  2015-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DNALYTICS BE (OTTIGNIES LOUVAIN LA NEUVE) coordinator 50˙000.00

Map

 Project objective

Arthritis, a group of diseases involving inflammation of joints with huge health and socio-economic impacts. Early Arthritis (EA) describes newly diagnosed arthritis (incidence 2/1000). An improved arthritis management requires to enhance the EA differential diagnostic efficacy and the adequacy of the therapeutic strategies. The earlier arthritis is addressed, the more likely its progression will be limited. A mistake in differential diagnostic leads to inappropriate treatments, resulting in useless expenses and serious side effects, unjustified. Current diagnostic techniques are unsatisfactory and the most used first line treatment, Methotrexate (MTX), is ineffective in about 40% of the patients. RheumaKit is a solution for clinicians for the early differential diagnostic of patients suffering from undifferentiated arthritis (UA, a subclass of EA). RheumaKit is based on a trancriptomic signature of about 100 genes complemented by 3 clinical factors. It provides a 90% accuracy for the Rheumatoid Arthritis (RA) vs non-RA distinction, far above the ACR/EULAR2010 criterion on the same patients. It also provides probabilities for Osteoarthritis and Seronegative Spondylarthropaties. The solution consists of a synovial biopsy collection and transportation kit (CE-marked May 2014), a central lab PCR procedure, and a web application computing the effective diagnostic on a cloud-computing infrastructure. Functional, technical, logistics aspects of RheumaKit have been validated. ADDITION aims at clinically validate on a larger patient cohort the existing RheumaKit signature for the differential diagnostic of most EA patients and validate the use of the existing RheumaKit signature as a tool to predict MTX response. ADDITION phase 2 will involve a prospective study on 500 to 1000 EA patients. The main phase 1 objectives are a feasibility study of the clinical and market aspects of ADDITION. The expected annual turnover is above 140M€-280M€ in EU within a few years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADDITION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ADDITION" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More